Hypogonadism – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030


 Hypogonadism in men, defined by a low serum testosterone concentration, causes a slew of symptoms such as decreased libido, erectile dysfunction, reduced ejaculate volume, loss of body and facial hair, weakness, decreased lean body mass, reduced bone density, increased body fat, fatigue, and anemia. Most notably, libido loss and erectile dysfunction (ED). Depressive symptoms, decreased cognitive abilities, irritability, and lethargy or energy loss are signs of low testosterone. Endogenous testosterone deficiency also hurts bone mass and is a significant risk factor for osteoporosis in men. Progressive loss of muscle mass and strength and testicular dysfunction often results in impaired sperm production. Unlike female menopause, which is a universal and abrupt aging process, not all men become testosterone deficient as they age. Even in their advanced years, a significant number of men remain eugonadal. However, as men age, they become increasingly likely to have conditions, such as cardiovascular disease, depression, osteoporosis, and diabetes, that occur concomitantly with decreased testosterone levels.

The prevalent cases of Hypogonadism affect an estimated 4 to 5 million men in the United States, although it may occur in men at any age.

Hypogonadism was found in 2.1 percent to 12.8 percent of middle-aged to older men in the general population, with an estimated incidence of 12 new cases per 1,000 people per year.

Patients with comorbid conditions, such as type 2 diabetes mellitus and obesity, had a higher prevalence. Approximately 10–12% of men with Hypogonadism were being treated with testosterone.

The competitive landscape of Hypogonadism includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Hypogonadism across the 8 MM market from the center of Excellence/ Public/ Private hospitals participated. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Hypogonadism Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Hypogonadism – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          LPCN 1021       Lipocine Inc.     Phase 3

2          DITEST Diurnal Limited  Phase 1

3          Testosterone enanthate auto-injector     Antares Pharma Inc.            Phase 3

4          BGS649            Mereo BioPharma         Phase 2

5          Oral Testosterone Undecanoate Clarus Therapeutics, Inc.            Phase 2

6          Corifollitropin alfa          Organon and Co            Phase 3

7          Testosterone Nasal Gel [Natesto]           Acerus Biopharma Inc.            Phase 1

8          Gonadorelin acetate      Ferring Pharmaceuticals            Phase 3

9          TSX-002           TesoRx Pharma, LLC    Phase 2

10        Enclomiphene   Repros Therapeutics Inc.           Phase 2

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more